Lumexa Imaging Holdings, Inc. (LMRI) stock intrinsic value fair value estimate & owner earnings analysis

Lumexa Imaging (formerly US Radiology Specialists) runs 188 outpatient diagnostic imaging centers (MRI, CT, X-ray, mammography and similar) in 13 states, concentrated in Texas, New Jersey, Georgia and the Carolinas, plus radiology physician practices and a teleradiology group. 102 centers are wholly owned or run through affiliated practices and are consolidated; the other 86 sit inside eight joint ventures with hospital systems in which Lumexa holds a minority stake. Those joint ventures do not appear in revenue; Lumexa books its share of their profit ($72M in 2025) and receives quarterly cash distributions ($65M in 2025, $80M in 2024). Consolidated revenue was $1.023B in 2025, up 7.8%, but the company has never earned a GAAP profit as a stand-alone business: net losses were $122M (2023), $94M (2024) and $47M (2025). Owner earnings. We start from operating cash flow, remove working-capital swings, subtract stock compensation (a real cost, $41.6M-$56.7M a year) and subtract maintenance spending on equipment. Because Lumexa buys much of its scanning equipment on finance leases ($30.5M of equipment in 2025 with no upfront cash), we count finance-lease principal payments alongside cash equipment purchases as capital spending; leaving them out would flatter the result. On that basis owners' cash was negative every year: -$0.82 a share in 2023, -$0.93 in 2024 and -$0.40 in 2025. The losses were driven by interest: about $130M a year was paid on a $1.2B term loan at SOFR + 4.75%. Business before lenders. Adding back cash interest shows what the centers themselves produce: about $73M in 2023, $64M in 2024 and $84M in 2025. We anchor on roughly $73M, the middle of those three years, because three years is all the history available and 2025 was helped by one-off items in both directions ($11.2M of old transaction costs paid, offset by lower JV distribution timing). The first half of 2026 was softer on a cash basis: operating cash flow of $35.7M, stock compensation of $25.0M (higher than 2025 after IPO grants) and $15.0M of equipment purchases, with transaction, ERP and recruiting costs the company says continue into 2026. Business cash flow grew about 32% in 2025; we assume a decline to about $64M in year 1 because of the higher stock compensation run rate and continuing one-off costs, not a continuation of 2025's jump. Debt. At June 30, 2026 Lumexa owed about $835M of long-term debt (the $825M Refinancing Term Loan at SOFR + 3.0%, about 6.7%, maturing December 2032, plus equipment notes) and about $55M of finance leases, against $70M of cash, of which we treat roughly $50M as surplus. Because the loan is floating at roughly 0.7 points above our benchmark for six more years, we add about $30M for its extra cost. Net debt used: about $870M on 96.0M diluted shares. The $250M revolver (undrawn, matures December 2030) gives liquidity, and nothing matures before 2030. Base case: business cash flow of $64M in year 1, $70M in year 2 as transaction and IT implementation costs roll off, then about $73M a year held flat thereafter. We credit no growth from new centers or acquisitions: de novo openings and roll-up acquisitions have been funded with borrowed money and IPO proceeds, not from internal cash, and the company has never generated owner cash after interest, so this growth is not in the bag. Population growth in its markets and the hospital JV pipeline are real but not secured. The business is worth about $1.21B, it owes about $0.87B, leaving about $336M, or $3.49 a share. Bear case: this business depends on Medicare and commercial payers, and the industry's own record includes the 2007 Deficit Reduction Act imaging cuts and the 2020 shutdown, when outpatient imaging volumes fell by half for several months. Our bear case starts at $55M and $50M in the first two years (stock compensation stays high, cost overruns continue), then a reimbursement or volume shock of that kind in year 3 that drops business cash flow to about -$10M because most costs (leases, radiologists, equipment) are fixed, followed by a two-year recovery to only $50M a year. In that year Lumexa would draw its revolver to meet about $55M of interest; with no maturity before 2030 lenders would allow one such year. The business would be worth about $760M against about $870M of debt, so shareholders would be left with nothing: the company would owe roughly $110M more than it is worth, about -$1.13 a share. Bull case: the refinanced, cheaper capital structure lets the centers' cash flow show through, transaction and ERP costs end in 2026, the joint ventures keep distributing at the 2024 level, and business cash flow reaches $75M, $82M and $86M in the first three years, then grows 2% a year from same-center volume and the hospital partnerships already in place. That is worth about $1.57B against $0.87B of debt, about $7.29 a share. What could make this wrong. The earnings level rests on only three years of history, all as a heavily indebted private-equity company with large one-off costs, so we are not highly confident in it; each $10M a year of sustained business cash flow moves the per-share value by roughly $1.75. Stock compensation is the second swing factor: at the first-half 2026 pace it is near $50M a year, almost two-thirds of what the centers generate before interest. The third is the joint ventures: about $65M-$80M a year of cash comes from centers Lumexa does not control, under agreements with hospital partners. With debt of about $870M ahead of shareholders, small changes in any of these move the equity value by a large proportion. Margin-of-safety price. Because the equity is a thin slice sitting on top of roughly $870M of debt, the shares are worth nothing in a realistic downturn and only about $3.50 if the business simply holds its level. Lumexa pays no dividend, so the entire return must come from the business proving its cash generation and paying down debt; the price assumes a four-to-five-year holding period. From $1.50 a share, the base case implies a value of about $3.50 over that period, roughly a 20% annual return, with room for the earnings level to come in somewhat lower. Above that price, a single bad reimbursement year would wipe out the return. The margin-of-safety price is $1.50. The previous estimate was prepared on a different basis (it did not subtract debt from a pre-interest value or count finance-lease equipment as capital spending), so those figures are not comparable.